Rigontec

About:

Rigontec is the leader in RIG-I targeting RNA therapeutics developing novel immuno-oncology treatment options.

Top Investors: Forbion Capital Partners, Wellington Partners, HTGF | High-Tech Gruenderfonds, Boehringer Ingelheim Venture Fund, MP Healthcare Venture Management

Description:

Rigontec is the leader in RIG-I targeting RNA therapeutics developing novel immuno-oncology treatment options.

Total Funding Amount:

29.3M EUR

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Martinsried, Bayern, Germany

Founded Date:

2014-01-01

Contact Email:

info(AT)rigontec.com

Founders:

Anna Schwickart-Halbe, Annegret Baey-Diepolder, Christine Schuberth Wagner, Gunther Hartmann, Marcel Renn, Veit Hornung

Number of Employees:

11-50

Last Funding Date:

2016-09-06

IPO Status:

Private

Industries: